Spyre Therapeutics (FRA:3920) Accounts Payable: €4.92 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3920 Spyre Therapeutics Inc FRA:3920
29 GF Score
Price €90.00
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics Accounts Payable?

Spyre Therapeutics FRA:3920 +2.86% 29 Accounts Payable is €4.92 Mil as of Mar. 2026. GuruFocus rates FRA:3920 with a GF Score™ of 29/100 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Spyre Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was €4.92 Mil.

Spyre Therapeutics's quarterly Accounts Payable increased from Sep. 2025 (€6.35 Mil) to Dec. 2025 (€7.60 Mil) but then declined from Dec. 2025 (€7.60 Mil) to Mar. 2026 (€4.92 Mil).

Spyre Therapeutics's annual Accounts Payable declined from Dec. 2023 (€0.82 Mil) to Dec. 2024 (€0.64 Mil) but then increased from Dec. 2024 (€0.64 Mil) to Dec. 2025 (€7.60 Mil).

Spyre Therapeutics Accounts Payable Related Terms

Spyre Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics Accounts Payable Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.94 0.64 0.82 0.64 7.60

Spyre Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.41 3.22 6.35 7.60 4.92
FRA:3920
29GF Score
Spyre Therapeutics Inc FRA:3920
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €4.92 Mil mean?
Spyre Therapeutics (FRA:3920) has a Accounts Payable of €4.92 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Spyre Therapeutics and its competitors.
Is Spyre Therapeutics' Accounts Payable too high?
Spyre Therapeutics' current Accounts Payable is €4.92 Mil. Overall, Spyre Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Accounts Payable compare to CRNX and PTGX?
Spyre Therapeutics' Accounts Payable of €4.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current Accounts Payable is €4.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spyre Therapeutics (FRA:3920) is currently considered Significantly Overvalued. The current Accounts Payable is €4.92 Mil. Spyre Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current Accounts Payable is €4.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
29GF Score

Get the complete analysis for FRA:3920

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€90.00
Price